Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?-Reference-Cited by-同舟云学术

Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

Published:2023-08 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Sanmamed Noelia,Gómez-Rivas Juan,Buchser David,Montijano Miguel,Gómez-Aparicio María Antonia,Duque-Santana Victor,Torres Lisselott,Zilli Thomas,Ost Piet,Maldonado Antonio,López-Campos Fernando^ORCID,Couñago Felipe

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference81 articles.

1. American Cancer Society. Cancer Facts & Figures 2022 [Internet]. [Accessed March 27, 2023]. Available from: https://www.cancer.org/research/cancer-factsstatistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

2. Prostate cancer incidence and survival, by stage and race/ethnicity — United States, 2001–2017;Siegel;MMWR Morb Mortal Wkly Rep,2020

3. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the european randomized study of screening for prostate cancer;Buzzoni;Eur Urol,2015

4. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;CA Cancer J Clin,1972

5. Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer;Miyake;Anticancer Res,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy;2023-10-16